Company Overview

CareDx, Inc. is a precision diagnostics company focused on improving outcomes for organ transplant patients. The company operates primarily in the molecular diagnostics and transplant healthcare industries, providing testing solutions that help clinicians monitor organ transplant rejection, assess patient risk, and manage long-term transplant care. CareDx’s business is centered on post-transplant patient management rather than therapeutic drugs or devices.

The company’s primary revenue drivers are its diagnostic testing services, most notably the AlloSure and AlloMap tests, which are used to monitor organ transplant rejection through non-invasive methods. CareDx primarily serves transplant centers, hospitals, and clinicians, with a strong concentration in heart and kidney transplant markets. Founded in 1998, CareDx evolved from an early-stage diagnostics company into a specialized transplant-focused platform through internal test development and strategic acquisitions that expanded its testing portfolio and data capabilities.

Business Operations

CareDx operates through a single, integrated diagnostics business model that combines laboratory-developed tests, data analytics, and clinical support services. Its core offerings include AlloSure, a donor-derived cell-free DNA test used to detect organ injury, and AlloMap, a gene expression profiling test used primarily in heart transplant surveillance. Revenue is generated largely through reimbursement for diagnostic testing performed in CareDx’s certified laboratories.

The company conducts most of its testing operations in the United States, with laboratory infrastructure designed to meet regulatory and payer requirements. CareDx controls proprietary testing technologies, clinical data platforms, and intellectual property related to transplant diagnostics. The company has expanded its operational capabilities through acquisitions, including Karius, Inc., which added advanced pathogen detection technology, and maintains relationships with transplant centers rather than large-scale joint ventures.

Strategic Position & Investments

CareDx’s strategy is focused on deepening its leadership in transplant diagnostics by expanding test adoption, broadening clinical utility, and integrating data-driven insights into transplant care. Growth initiatives include increasing penetration in kidney transplant monitoring, developing additional applications for cell-free DNA testing, and enhancing longitudinal patient management through digital and data tools.

The company has made targeted acquisitions to complement its core transplant franchise, most notably Karius, Inc., which strengthened CareDx’s capabilities in infectious disease diagnostics relevant to immunosuppressed transplant patients. CareDx also invests in clinical studies and real-world evidence generation to support reimbursement coverage and guideline inclusion, positioning itself at the intersection of diagnostics, data, and transplant medicine.

Geographic Footprint

CareDx is headquartered in Brisbane, California, and its primary operational footprint is in North America, where the majority of its revenue is generated. The company’s diagnostic tests are widely used across transplant centers in the United States, which remains its most significant market due to reimbursement structures and transplant volumes.

Internationally, CareDx has limited but growing exposure, with test availability and partnerships in select regions outside the U.S. The company’s global influence is primarily indirect, driven by the adoption of its technologies in leading transplant programs and the publication of clinical data that supports broader international use.

Leadership & Governance

CareDx is led by an executive team with experience in diagnostics, healthcare, and life sciences, emphasizing clinical evidence generation, disciplined growth, and operational focus in a regulated healthcare environment. The leadership philosophy centers on improving transplant patient outcomes through scientifically validated, non-invasive diagnostic solutions.

Key executives include:

• John W. Hanna – President and Chief Executive Officer
• Mitchell H. Pollack – Chief Financial Officer
• Sean McCarthy – Chief Commercial Officer
• Michael McCloskey – Chief Technology Officer
• Abbas Rana – Chief Medical Officer